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Abstract
Background: The metabolic syndrome (MetS) is a cluster of metabolic abnormalities comprising
visceral obesity, dyslipidaemia and insulin resistance (IR). With the onset of IR, the expression of
lipoprotein lipase (LPL), a key regulator of lipoprotein metabolism, is reduced. Increased activation
of glucocorticoid receptors results in MetS symptoms and is thus speculated to have a role in the
pathophysiology of the MetS. Glycyrrhizic acid (GA), the bioactive constituent of licorice roots
(Glycyrrhiza glabra) inhibits 11β-hydroxysteroid dehydrogenase type 1 that catalyzes the activation
of glucocorticoids. Thus, oral administration of GA is postulated to ameliorate the MetS.
Results: In this study, daily oral administration of 50 mg/kg of GA for one week led to significant
increase in LPL expression in the quadriceps femoris (p < 0.05) but non-significant increase in the
abdominal muscle, kidney, liver, heart and the subcutaneous and visceral adipose tissues (p > 0.05)
of the GA-treated rats compared to the control. Decrease in adipocyte size (p > 0.05) in both the
visceral and subcutaneous adipose tissue depots accompanies such selective induction of LPL
expression. Consistent improvement in serum lipid parameters was also observed, with decrease
in serum free fatty acid, triacylglycerol, total cholesterol and LDL-cholesterol but elevated HDL-
cholesterol (p > 0.05). Histological analysis using tissue lipid staining with Oil Red O showed
significant decrease in lipid deposition in the abdominal muscle and quadriceps femoris (p < 0.05)
but non-significant decrease in the heart, kidney and liver (p > 0.05).
Conclusion: Results from this study may imply that GA could counteract the development of
visceral obesity and improve dyslipidaemia via selective induction of tissue LPL expression and a
positive shift in serum lipid parameters respectively, and retard the development of IR associated
with tissue steatosis.
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Background
Lipoprotein lipase (LPL) is the major enzyme responsible
for the hydrolysis of circulating triacylglycerol (TAG) moi-
ety of both classes of TAG-rich lipoproteins; the chylomi-
crons and very-low-density lipoprotein (VLDL),
generating free fatty acids (FFA) that are either oxidized in
the muscles or re-esterified in the adipose tissues, and
glycerol that is returned to the liver. LPL plays a central
role in overall lipoprotein metabolism, where (i) the suc-
cessive interaction of VLDL with LPL generates the low-
density lipoproteins (LDL) that are involved in forward
cholesterol transport and (ii) the remnant lipoprotein
particles so formed from LPL catalysis contributes to the
maturation of high-density lipoprotein (HDL) precursors,
the latter of which is then involved in reverse cholesterol
transport [1,2]. Perturbation in LPL activity could there-
fore lead to significant metabolic consequences and LPL
has been implicated in pathophysiological conditions
characterized by marked hypertriglyceridaemia, such as
that observed in the metabolic syndrome (MetS).
The MetS refers to a constellation of metabolic abnormal-
ities characterized by the co-existence of insulin resistance
(IR), visceral obesity, hyperglycaemia, hypertension and
dyslipidaemia. The syndrome has become a recognizable
clinical cluster of risk factors that are predictive of the pro-
gression to cardiovascular disease and type 2 diabetes
mellitus (T2DM) [3]. Both visceral obesity and IR are rec-
ognized as the major determinants in the development of
the MetS [4] and in fact, over 80% of individuals with
T2DM are obese and virtually all are insulin resistant [5].
Differing definitions of the syndrome have been put for-
ward by various global health agencies such as the World
Health Organization (WHO), the National Cholesterol
Education Program Adult Treatment Panel III (NCEP ATP
III) and the International Diabetes Federation (IDF) but
all such definitions point to a common agreement that the
syndrome results in increased atherogenesis and death
from myocardial infarction [4]. Thus, increased attention
has been channeled to the improvement of lipid abnor-
malities characteristic of the MetS.
Dyslipidaemia, the hallmark of the MetS which is mani-
fested in the more severe form in T2DM, is characterized
by (i) increased flux of FFA, (ii) elevated TAG level (hyper-
triglyceridaemia), (iii) reduced HDL level and (iv) a pre-
dominance of small, dense LDL. Elevated plasma FFA is
viewed as the primary defect leading to the development
of dyslipidaemia [6,7] and IR [8]. With the ensuing IR,
LPL expression is reduced and LPL activity becomes
diminished [9,10]. This amplifies the extent of the hyper-
triglyceridaemia by favouring the accumulation of TAG-
rich chylomicrons and VLDL in the circulation. The
increase in small, dense LDL and low HDL is secondary to
this elevated TAG level, where through the action of
cholesteryl ester transfer protein (CETP), TAG enrichment
of both the HDL and LDL particles occurs. TAG-rich LDL
particles are good substrate to be acted upon by hepatic
lipase (HL), producing a population of small, dense,
lipid-poor LDL. Similarly, HL-mediated hydrolysis of
TAG-rich cholesterol-poor HDL leads to an accelerated
degradation of apo A-I, the major protein of HDL. This
causes the HDL to be rapidly cleared from the plasma
[6,7,11]. In addition to such serum lipid perturbations,
studies have also indicated that tissue lipid accumulation
is associated with obesity-related IR and T2DM where
both conditions are associated with increased tissue lipid
[12,13].
Increased activation of glucocorticoid receptors has been
implicated in the development of MetS symptoms such as
visceral obesity and hyperlipidemia. Pharmacological
inhibition of the enzyme 11β-hydroxysteroid dehydroge-
nase type 1 (11β-HSD1) that acts to regenerate active glu-
cocorticoids from inactive 11-keto metabolites has been
proposed as a therapeutic target for the treatment of MetS
following the association of such inhibition with a cardi-
oprotective lipid profile [14,15]. Glycyrrhizic acid (GA),
the primary bioactive constituent of the roots of the shrub
Glycyrrhiza glabra and its pharmacologically active metab-
olite glycyrrhetic acid (GE) act as potent, non-selective
inhibitors of both isoforms of 11β-HSD [16,17]. To date
however, the effects of orally-administered GA on LPL
expression and on the modulation of serum lipid and tis-
sue lipid deposition have yet to be conducted. The objec-
tives of this study are therefore to determine and compare
each of these parameters between GA-treated and non-
treated rats following daily oral administration of GA for
one week in the former.
Results
GA treatment led to increase in LPL expression of all 
studied tissues
LPL expression in the GA-treated rats was increased in all
studied tissues (Figure 1), of which included the heart,
liver, kidney, quadriceps femoris (QF), abdominal muscle
(AM), visceral adipose tissue (VAT) and subcutaneous adi-
pose tissue (SAT). The QF demonstrated the highest
increase with a fold difference of 2.02 ± 0.89, representing
a significant 102% increase (p < 0.05). This was followed
by the AM (1.87 ± 1.61 fold; 87% increase), kidney (1.43
± 0.93 fold; 43% increase), liver (1.29 ± 1.01 fold; 29%
increase) and the VAT (1.08 ± 0.48 fold; 8%); all of which
exhibited no significance difference between the control
and GA-treated group (p > 0.05). Increase in LPL expres-
sion was similar in the heart and SAT (1.04 ± 0.48; 4%
increase) but these were not significant (p > 0.05).
GA treatment reduced the size of adipocytes
Mean area of both VAT and SAT adipocytes showed non-
significant decrease in the GA-treated group compared to
the control (p > 0.05) (Figure 2). In the VAT, mean adi-Lipids in Health and Disease 2009, 8:31 http://www.lipidworld.com/content/8/1/31
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pocyte area in the control group was 1449.96 ± 156.58
μm2 while that in the treated group was 1206.58 ± 239.48
μm2. In the SAT, mean adipocyte area was 1419.91 ±
141.14 μm2 in the control group, compared to a mean of
1161.18 ± 143.26 μm2 in the treated group. These repre-
sented a 16.79% and 18.22% reduction in the area of adi-
pocytes in VAT and SAT respectively. Sections of these
tissues are shown in Figure 3.
GA treatment led to improvement in all serum lipid 
parameters
Consistent improvement in all serum lipid parameters
were observed in the GA-treated rats relative to the control
(p > 0.05) (Figure 4). Mean serum TAG showed a 14.73%
reduction (control, 1.29 ± 0.31 mmol/L; treated, 1.10 ±
0.27 mmol/L) while that of total cholesterol charted a
reduction of 12.99% (control, 3.31 ± 0.60 mmol/L;
treated, 2.88 ± 0.43 mmol/L) and that of LDL-cholesterol
a 36.96% reduction (control, 1.38 ± 0.34 mmol/L;
treated, 0.87 ± 0.27 mmol/L). HDL-cholesterol on the
other hand was elevated by 11.85% (control, 1.35 ± 0.19
mmol/L; treated, 1.51 ± 0.47 mmol/L). Serum FFA also
exhibited a similar trend of improvement with a reduction
of 8.51% in the treated group (control, 0.47 ± 0.07 mmol/
L; treated, 0.43 ± 0.07 mmol/L).
GA treatment reduced tissue lipid deposition
Lipid deposition demonstrated a decrease across all stud-
ied tissues in the GA-treated group (Figure 5). Levels of
lipid deposition was highest in the liver and recorded a
21.86% decrease (control, 582.44 (23.50–1939.66) AU;
treated, 55.14 (23.13–1830.91) AU) following GA treat-
ment. The kidney demonstrated a 25.11% decrease (con-
trol, 137.54 (11.55–392.10) AU; treated, 103.00 (13.10–
228.00) AU). No significant difference between the con-
trol and treated groups were observed in both tissues (p >
Fold difference in tissue LPL expression of the GA-treated  group Figure 1
Fold difference in tissue LPL expression of the GA-
treated group. Relative tissue LPL expression following GA 
treatment is shown in decreasing order. In this analysis, β-
actin (BAC) gene was used as the endogenous reference, 
GA-treated group as the target and control group as the cal-
ibrator. * denotes p < 0.05.
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Mean area of adipocytes (μm2) of control and GA-treated  rats Figure 2
Mean area of adipocytes (μm2) of control and GA-
treated rats. Size of adipocytes demonstrated a decrease in 
both the VAT and SAT depot after seven days of oral GA 
administration (p > 0.05).
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H&E-stained adipose tissues Figure 3
H&E-stained adipose tissues. Representative sections of 
H&E-stained (A) VAT and (B) SAT in (i) control and (ii) GA-
treated rats at 100× magnification. The adipocytes appear as 
empty, unstained vacuoles with the nucleus compressed to 
one side of the cell while the cytoplasm is reduced to only a 
small rim at the periphery of the cell. Arrows indicate exam-
ples of cytoplasm (C) and nucleus (N).Lipids in Health and Disease 2009, 8:31 http://www.lipidworld.com/content/8/1/31
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0.05). Among the muscles, the QF and the AM showed
significantly reduced lipid deposition in the GA-treated
group relative to the control (p < 0.05), with a decrease of
42.21% and 33.96% in each tissue respectively (QF: con-
trol, 191.28 (28.85–606.17) AU; treated, 110.54 (12.21–
594.28); AM: control, 141.29 (11.77–356.51) AU;
treated, 93.31 (22.69–297.13) AU). Lastly, lipid deposi-
tion in the heart showed a non-significant 6.74% decrease
(control, 149.56 (26.58–327.91) AU; treated, 139.48
(47.74–268.54) AU). Sections of these tissues are
depicted in Figure 6.
GA treatment did not induce an increase in systolic blood 
pressure
Systolic blood pressure of control and GA-treated rats
fluctuated within a narrow range throughout the duration
Serum lipid of control and GA-treated rats Figure 4
Serum lipid of control and GA-treated rats. Mean 
serum TAG, total cholesterol, LDL-cholesterol and FFA 
(mmol/L) of GA-treated rats showed reduction after seven 
days of oral GA administration while that of HDL-cholesterol 
showed an increase (p > 0.05 for all parameters).
0.00
0.50
1.00
1.50
2.00
2.50
3.00
3.50
4.00
4.50
TAG Total 
Cholesterol
HDL 
Cholesterol
LDL  
Cholesterol
FFA
M
e
a
n
 
(
m
m
o
l
/
L
)
Serum Lipid Parameters
Control 
GA-Treated 
Levels of lipid deposition in non-adipose tissues Figure 5
Levels of lipid deposition in non-adipose tissues. Sec-
tions of ORO-stained tissues were converted to a grayscale 
each time for lipid staining quantification. * denotes p < 0.05.
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ORO-stained tissues Figure 6
ORO-stained tissues. Representative sections of ORO-
stained (A) heart, (B) kidney, (C) liver, (D) AM and (E) QF in 
(i) control and (ii) treated rats at 400× magnification. Distinct 
spots of ORO-stained lipid were observed across all tissue 
sections with considerable heterogeneity in lipid content 
between tissues. Arrows indicate examples of lipid droplets.Lipids in Health and Disease 2009, 8:31 http://www.lipidworld.com/content/8/1/31
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of treatment (Figure 7). Systolic blood pressure of the con-
trol and GA-treated rats were compared on Days 0, 2, 4
and 6 of the treatment duration. No significant difference
(p > 0.05) in mean systolic blood pressure was observed
between the control and treated groups and within each
group on each of these days.
Discussion
IR has been recognized as the central component of the
MetS which is associated with hyperinsulinaemia, glucose
intolerance, dyslipidaemia and visceral obesity [4]. With
the onset of IR, the activity of LPL, a key regulator of lipo-
protein metabolism that is subject to insulin regulation,
has been reported to be reduced both in the adipose tis-
sues and muscles [18,19]. Insulin has been implicated in
the biosynthesis of LPL [10] where the insulin-signaling
pathway activates the class of nuclear receptors known as
the peroxisome proliferator-activator receptor (PPAR).
The isoforms of these, PPARα and PPARγ, then bind to the
peroxisome proliferator respondse element (PPRE) at the
LPL gene promoter to up-regulate LPL expression [20].
In this study, inhibition of 11β-HSD1 by GA could not
account adequately for the observed increase in tissue LPL
expression. Despite the inhibitory effects of glucocorti-
coids on LPL protein synthesis and mRNA levels, such
observations were only observed in the adipose tissues
[21]. Therefore, the induction of LPL expression in this
study points to a separate mode of action of GA where GA
is postulated to activate the PPAR class of nuclear recep-
tors. This is based on the consistency of several findings,
where (i) triterpenoids have been reported to lead to the
transactivation of PPAR-γ [22,23] and more importantly
(ii) PPAR-α and -γ agonists have been shown to reduce the
expression and activity of 11β-HSD1 [24]. Thus, GA, both
a triterpenoid and an 11β-HSD1 inhibitor may act as a lig-
and to the PPAR. Interestingly, 11β-HSD1 knock-out mice
also show an elevation of PPAR-α mRNA. PPAR-α is phys-
iologically induced by glucocorticoids and its elevation
following 11β-HSD1 inhibition may have arisen from
increased circulating plasma corticosterone due to
impaired 11β-HSD1-mediated negative feedback upon
the hypothalamic-pituitary-adrenal axis [14]. This
increased PPARα may then act in return to up-regulate
LPL. Thus, GA-mediated activation of the PPAR class of
nuclear receptors may be direct or indirect.
PPAR-α plays a key role in regulating pathways of β-oxida-
tion and is expressed abundantly in tissues metabolizing
high amounts of FFA, such as the liver, kidney, heart and
muscles while PPAR-γ is expressed primarily in the adi-
pose tissues where it triggers adipocyte differentiation and
lipogenesis [25,26]. With reference to Figure 1, increased
LPL expression was consistently higher in tissues charac-
terized by high PPAR-α expression (QF, AM, kidney and
liver) as compared to tissues in which PPAR-γ predomi-
nates (VAT and SAT). One exception however was seen in
the heart that has a relative LPL expression comparable to
that of the adipose tissues. Such discrepancy may be due
to the lower distribution of GA into the heart as compared
to all other tissues examined in this study [27]. The selec-
tive pattern of tissue LPL induction suggested that GA
exhibits greater potency in activating PPAR-α than PPAR-
γ. Such pattern of tissue LPL induction have been advo-
cated for the correction of visceral obesity as it could lead
to the competitive delivery of FFA away from the more
pathogenic visceral fat depot to other less pathogenic
depots [28].
This postulation was then confirmed in the study through
the measurement of adipocyte size in both control and
GA-treated rats. With reference to Figure 2, size of adi-
pocytes exhibited a decrease in both the VAT and SAT fol-
lowing GA treatment. The overall results have therefore
shown that by reducing visceral fat accumulation, GA has
the potential to counteract the very fundamental abnor-
mality that contributes to the development of the MetS,
i.e. visceral obesity [8].
Accompanying the increase in tissue LPL expression and
decrease in adipocyte size was the consistent improve-
ment in serum lipid parameters of the GA-treated rats rel-
ative to the control; with a reduction in serum FFA, TAG,
total cholesterol and LDL-cholesterol and elevation of
HDL-cholesterol. The GA-induced decrease in serum FFA
Evaluation of systolic blood pressure Figure 7
Evaluation of systolic blood pressure. Day-to-day mean 
systolic blood pressure (mmHg) of control and treated rats 
over the duration of treatment. No significant difference was 
observed in each of the days between both groups and within 
each group (p > 0.05).
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appears to be of critical importance due to the role of FFA
in initiating the development of IR, β-cell dysfunction and
dyslipidaemia [5,7]. The observed decrease in serum FFA
may be attributed to increased tissue uptake. Berthiaume
et al. [29] has demonstrated that inhibition of 11β-HSD1
is associated with a concomitant increase in protein con-
tent of plasma membrane fatty acid-binding protein
(FABPpm) that facilitates the entry of FA into cells. In addi-
tion, PPAR-α agonists have also been reported to induce
the activities of fatty acid transporter protein (FATP) and
acyl-CoA synthetase [30], where the former mediates FFA
uptake and the latter is involved in the activation of FFA
that then facilitates its β-oxidation [31,32]. Activation of
acyl-CoA synthetase therefore promotes the oxidation of
FFA to prevent the saturation of cellular FA binding and
transport [32]. This supports further the decrease in lipid
deposition in the studied tissues despite increased FFA
uptake.
The decrease in serum TAG did not appear secondary to
the reduction in serum FFA and may be mostly attributed
to the action of GA. Inhibition of 11β-HSD1 has been
shown to reduce hepatic VLDL secretion [29] which may
have been driven by increased hepatic FFA oxidation due
to the induced expression of fat-catabolizing enzymes
[14]. Hepatic VLDL secretion is regulated by the amount
of lipids available for the assembly of VLDL [29]. Extracel-
lular FFA entering the liver is either oxidized or esterified
to form a cytosolic pool of TAG; the TAG required for
VLDL assembly is recruited from this pool. Physiologi-
cally, extracellular FFA acts to boost VLDL secretion by
expanding the size of this intrahepatic TAG pool [33].
With increased FA oxidation however, the drive for the
VLDL assembly pathway is subsequently attenuated.
The increase in HDL-cholesterol following GA adminis-
tration may be due to the increased production of apo A-
I, the major protein of HDL that is subjected to accelerated
catabolism in the MetS [7]. Apo A-I mRNA has been
shown to be significantly elevated in 11β-HSD1 knock-
out mice [14] and following PPAR-α activation [30]. Since
the rate of HDL synthesis is dependent on the production
of apo A-I [34], this has been speculated as the HDL-
increasing mechanism of GA.
Despite lacking benefits of increased LPL expression in
this study, such LPL induction by GA may be pivotal in the
amelioration of lipid parameters in dyslipidaemic sub-
jects. In the lean rats employed in this study, the serum
TAG measured after a 12-h fast reflects only the VLDL frac-
tion. Serum chylomicrons have a half life of 13–14 min-
utes and would be cleared from circulation within this
fasting period [35]. In dyslipidaemic subjects however,
hypertriglyceridaemia is attributed to the prolonged
retention of both chylomicrons and VLDL due to inhib-
ited lipolysis of both particles following decreased LPL
levels [8]. Therefore, in the dyslipidaemic state, induced
LPL may contribute to the increased clearance of such
lipoproteins to reduce serum TAG. Furthermore, the
development of small, dense LDL and the reduction in
HDL seen in the dyslipidaemic state are attributed to
CETP-mediated lipid exchange between both lipoprotein
particles and TAG-enriched VLDL particles. Such exchange
is substrate-rather than enzyme-driven [36]. The increased
catabolism of TAG-enriched VLDL by LPL may thus serve
to positively re-modulate HDL and LDL profile in dyslip-
idaemia.
The observed decrease in lipid deposition across all stud-
ied tissues may be consequential of increased lipid oxida-
tion in these tissues following GA administration.
Previous reports have suggested that increased tissue lipid
content in the obese state is related to decreased activity of
oxidative enzymes [12]. In this study, increase in enzymes
of  β-oxidation such as acyl-CoA synthetase, mitochon-
drial carnitine palmitoyltransferase-I and acyl-CoA oxi-
dase were postulated to be induced through (i) direct
activation of PPAR-α by GA, (ii) increased expression of
PPAR-α following inhibition of 11β-HSD1 [14], or (iii)
activation of PPAR-α by LPL-generated FFA that serves as
natural PPAR-α ligands [37]. All the enzymes aforemen-
tioned carry a PPRE in the promoter region [30,38,39].
The last postulation showed consistency with the results
of the study where significant decrease in lipid deposition
was observed in the AM and QF, in agreement with their
higher increase in LPL expression compared to all other
tissues. In addition to the current study, Berthiaume et al.
[29] has also demonstrated that inhibition of 11β-HSD1
was associated with a reduction in tissue TAG content and
increased FFA oxidation.
TAG is present in all cell types and intracellular storage of
these neutral lipids occurs within lipid droplets. The adi-
pose tissue and liver are the principal stores of TAG,
explaining the high levels of lipid deposition in the liver,
while other cell types store small quantities of these. Tis-
sue TAG storage occurs in any quantities, and in the liver
for example, TAG storage may range up to 10-fold [33].
This explains the large range of lipid deposition in tissues
as observed in the study.
Obesity and T2DM has been associated with tissue lipid
accumulation and such ectopic TAG accumulation, also
known as tissue steatosis, is implicated in the impairment
of insulin signaling [12,13]. These lipotoxic effects are not
exerted by TAG itself, but through TAG-derived bioactive
lipid metabolites such as long chain fatty acyl-CoA, dia-
cylglyerol and ceramide that activate several serine kinases
to block insulin signal transduction [26]. In addition,
lipid accumulation in the pancreatic islets would furtherLipids in Health and Disease 2009, 8:31 http://www.lipidworld.com/content/8/1/31
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impair insulin secretion where both ceramide and the
nitric oxide generated from surplus unoxidized FFA
induces β-cell apoptosis in the pancreatic islet [5]. T2DM
has been postulated to only develop in such setting of
concurrently occurring IR and β-cell failure [40]. With the
demonstrated ability of GA to reduce tissue TAG accumu-
lation therefore, GA exhibits the potential to revert such
lipotoxicity exerted by tissue TAG excess and thereby serve
to prevent the onset of T2DM.
The analysis of systolic blood pressure was conducted to
determine the occurrence of the reported side effects of
GA intake. Chronic administration of GA has been associ-
ated with the development of pseudoaldosteronism, of
which includes symptoms such as electrolyte imbalance
and increased blood pressure. This results from the non-
selective nature of both GA and GE that inhibits not only
11β-HSD1 but also 11β-HSD2 [17]. In this study, one
week administration of GA did not induce an increase in
systolic blood pressure. The positive effects arising from
the inhibition of 11β-HSD1, such as modulation of serum
lipid, that is more readily observable compared to the side
effects arising from the inhibition of 11β-HSD2, such as
an increase in blood pressure, is possibly due to different
potency of GA in inhibiting the two isoforms of the
enzyme. Shimoyama et al. [41] has reported that GE, the
active metabolite of GA, is more effective in inhibiting
11β-HSD1 than 11β-HSD2. The IC50 for the two enzymes
are 0.09 μM and 0.36 μM respectively. This may signify
that the impact of GA on systolic blood pressure may be
observed if treatment duration was prolonged, or by
increasing the treatment dosage within the same duration.
Nevertheless, Quaschning et al. [42] has demonstrated
that the use of aldosterone and endothelin receptor antag-
onists could normalize GA-induced blood pressure. The
combinatorial use of GA and such antagonists may there-
fore represent a new therapeutic approach for patients
with MetS; allowing patients to harbour the benefits from
GA itself and simultaneously eliminating the possible side
effects.
Conclusion
Daily oral administration of 50 mg/kg of GA for a week
led to increased LPL expression predominantly in the
non-adipose tissues, with significant increase in the QF.
Together with the reduction in size of adipocytes in both
the VAT and SAT, this may suggest that GA could divert
FFA away from the pathogenic visceral depot to the oxida-
tive tissues, thus curbing visceral obesity. GA also modu-
lated serum lipid and the consistent pattern of
improvement of each lipid parameter; namely, serum
FFA, TAG, total cholesterol, HDL-cholesterol and LDL-
cholesterol, points to the ability of GA to cause a benefi-
cial shift to a less atherogenic lipid profile. The decrease in
tissue lipid deposition across all the non-adipose tissues
studied indicated that lipid did not accumulate in these
despite increased LPL expression, possibly due to an
accompanying increase in β-oxidation. GA may therefore
retard the development of IR associated with tissue steato-
sis.
Methods
Animals and treatment
The use and handling procedure of animals in this
research project had been approved by the Monash Uni-
versity Animal Ethics Committee (AEC Approval Number:
SOBSB/MY/2007/22). 16 male Rattus norvegicus Sprague-
Dawley rats weighing between 160–200 g were supplied
by Universiti Malaya Animal House (Malaysia) and were
housed individually in polypropylene cages in a room
kept at 23°C on a 12-h light: 12-h dark cycle (lights on at
0800 hours). The rats were randomly segregated into two
groups of eight; representing the control and GA-treated
groups. The GA-treated group was given 50 mg/kg of GA
daily per oral (p.o.) while the control group given tap
water without GA. All animals were fed ad libitum with
free access to standard rat chow (Glenn Forrest Stock-
feeder, Australia) and drinking water for the one week
duration of treatment.
Systolic blood pressure measurement
Systolic blood pressure was measured by tail cuff plethys-
mography using the NIBP controller (ADInstruments,
Australia). Conscious rats were placed into a plastic
restrainer and a tail-cuff with a pulse transducer was
applied onto the tail. The tail was heated using a table
lamp. Rats were allowed to habituate to the procedure for
7 days prior to start of the experiment. The recording and
determination of blood pressure were performed using
the Chart recording software and a final reading was aver-
aged out from at least 10 consecutive readings. This proce-
dure was performed every alternate day.
Blood and tissue sampling
At the end of the treatment period, all rats were humanely
sacrificed between 0800 to 1000 hours on the 8th day of
treatment after a 12-h fast. All rats were anaesthetized via
intraperitoneal injection of 150 mg/kg of sodium pento-
barbital (Nembutal) prior to exsanguination. Blood was
drawn from the cardiac ventricle via the apex and was cen-
trifuged at 12,000 × g for 10 minutes. The resulting serum
supernatant was then rapidly aliquoted into microtubes
and kept frozen at -80°C until required for analysis. The
seven tissues of interest; heart, liver, kidney, AM, QF and
VAT and SAT were promptly harvested, all of which were
placed into individual cryovials (Nalgene, USA) and
immediately snap-frozen in liquid nitrogen. These were
then stored at -80°C until required for analysis. In addi-Lipids in Health and Disease 2009, 8:31 http://www.lipidworld.com/content/8/1/31
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tion, a fraction of VAT and SAT were immersed in 10%
neutral-buffered formalin in individual universal bottles
for histological analysis.
Plasma lipid parameters
Total cholesterol, TAG and FFA were measured with Ran-
dox CH200 Cholesterol kit (Randox, UK), Wako Triglyc-
eride E kit (Wako, Japan) and Randox FA115 Non-
Esterified Fatty Acids kit (Randox, UK) respectively. To
determine the level of HDL-cholesterol, HDL-cholesterol
was first separated from the LDL and VLDL fraction by
precipitation of the latter two using the Randox CH203
HDL Precipitant (Randox, UK), followed by a cholesterol
assay using the Randox CH200 Cholesterol kit (Randox,
UK). LDL-cholesterol was calculated using the Friedewald
formula, using the levels of total cholesterol, TAG and
HDL cholesterol obtained [43].
RNA extraction and cDNA synthesis
Total RNA extraction of the heart, liver, kidney, AM and
QF was performed using the Qiagen RNeasy Mini Kit
(Qiagen, USA) while that of the VAT and SAT with the
Qiagen RNeasy Lipid Tissue Mini Kit (Qiagen, USA). RNA
purity was performed by measuring the absorbance of the
diluted RNA at 260 and 280 nm. RNase-free DNase treat-
ment was performed using Promega RQ1 RNase-free
DNase (Promega, USA) and cDNA synthesis was per-
formed using the Qiagen Omniscript Reverse Tran-
scriptase kit (Qiagen, USA).
Real time reverse transcription polymerase chain reaction 
(qRT-PCR)
The expression of LPL was determined by qRT-PCR using
the LPL forward and reverse primers 5'-CAGCAAGGCAT-
ACAGGTG-3' and 5'-CGAGTCTTCAGGTACATCTTAC-3'
and the probe 5'-(6-FAM) TTCTCTTGGCTCTGACC
(BHQ1)-3' that are specific for Rattus norvegicus LPL
mRNA [GenBank: BC081836] and normalized to the β-
actin (BAC) gene with the forward and reverse primers 5'-
GTATGGGTCAGAAGGACTCC-3' and 5'-GTTCAATGGG
GTACTTCAGG-3' and the probe 5'-(TET) CCTCTCTT-
GCTCTGGGC (BHQ1)-3' specific for Rattus norvegicus
BAC mRNA [GenBank: BC063166]. The comparison of
LPL expression between control and GA-treated rats were
performed using the Comparative Ct (ΔΔCt) Method,
with BAC as reference, GA-treated group as target and con-
trol group as calibrator. Agarose gel electrophoresis was
carried out on amplicons generated from qRT-PCR reac-
tion to ensure primer specificity.
Tissue lipid staining
Frozen tissues were cut into small cubes of approximately
5 × 5 × 5 mm on and embedded using the Optimal Cut-
ting Temperature (OCT) Compound (Leica, Germany).
Cryosectioning was performed at a temperature of -25°C
where the embedded tissues were sectioned into 5 μm
slices and adhered onto glass slides. Staining with Oil Red
O (ORO) was performed in accordance to Koopman et al.
[44] and captured at 400× magnification. Lipid deposi-
tion was quantified as specified by Goodpaster et al. [12].
Images were transferred to Image J software and converted
to grayscale. Threshold for the intensity of staining was
adjusted in order to pick up only the droplets of lipid; the
full-range being from 0 to 255 arbitrary units (AU), where
0 represents complete staining and 255 represents no
staining. For lipid quantification, pixels with intensities of
≤ 150 ± 30 AU were quantified. Lipid deposition were
expressed in AU and calculated as:
Eight contiguous views per tissue section were captured
and analyzed for the lipid content. The level of lipid dep-
osition of each tissue section was calculated as the average
of these eight values.
Morphometric analysis of adipocytes
Adipose tissues that were fixed in 10% neutral-buffered
formalin as aforementioned were processed by a Leica TP
1020 Automatic Tissue Processor and embedded in paraf-
fin. 5 μm thick tissue sections were then stained with hae-
matoxylin and eosin (H&E) followed by the measurement
of the size of 100 adipocytes (μm2) per field view per tis-
sue section at 100× magnification.
Statistical analysis
Statistical analysis of LPL expression was performed using
the Relative Expression Software Tool (REST©) MCS Beta
2006 while that of all other parameters was performed
using the Statistical Package for the Social Sciences (SPSS)
Version 16.0. Data distribution was analyzed using the
Kolmogorov-Smirnov test. Parametric data were then ana-
lyzed with independent t-test and are presented as mean ±
standard error while non-parametric with Mann-Whitney
U-test and are reported as median (minimum – maxi-
mum). In all analyses, a p-value ≤ 0.05 was considered sig-
nificant.
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ceps femoris; SAT: subcutaneous adipose tissue; T2DM:
type 2 diabetes mellitus; TAG: triacylglycerol; VAT: visceral
adipose tissue; VLDL: very-low-density lipoprotein.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
WYAL was involved in all bench work, data acquisition,
analysis and interpretation and manuscript preparation.
YYC had part in the optimization of the qRT-PCR condi-
tions and SYL had part in histological work. SHT, KAK and
SNASH participated in the coordination of the study and
helped in drafting the manuscript. All authors read and
approved the final manuscript.
Acknowledgements
The study is funded in part by a grant from the Malaysian Ministry of Sci-
ence, Technology and Innovation (02-02-10-SF0003).
References
1. Preiss-Landi K, Zimmermann R, Hammerle G, Zechner R: Lipopro-
tein lipase: the regulation of tissue specific expression and its
role in lipid and energy metabolism.  Curr Opin Lipidol 2002,
13(5):471-481.
2. Pillarisetti S, Saxena U: Lipoprotein lipase as a therapeutic tar-
get for dyslipidemia.  Front Biosci 2003, 8:d238-241.
3. Balkau B, Valensi P, Eschwege E, Slama G: A review of the meta-
bolic syndrome.  Diabetes Metab 2007, 33:405-413.
4. Fulop T, Tessier D, Carpentier A: The metabolic syndrome.
Pathologie Biologie 2006, 54:375-386.
5. Boden G, Shulman GI: Free fatty acids in obesity and type 2 dia-
betes: defining their role in the development of insulin resist-
ance and beta-cell dysfunction.  Eur J Clin Invest 2002,
32(3):14-23.
6. Krauss R: Lipids and Lipoproteins in Patients With Type 2
Diabetes.  Diabetes Care 2004, 27(6):1496-1504.
7. Kolovou GD, Anagnostopoulou KK, Cokkinos DV: Pathophysiol-
ogy of dyslipidaemia in the metabolic syndrome.  Postgrad Med
J 2005, 81:358-366.
8. Lann D, LeRoith D: Insulin Resistance as the Underlying Cause
for the Metabolic Syndrome.  Med Clin N Am 2007, 91:1063-1077.
9. Mead JR, Irvine SA, Ramji DP: Lipoprotein lipase: structure, func-
tion, regulation and role in disease.  J Mol Med 2002, 80:753-769.
10. Kageyama H, Hirano T, Okada K, Ebara T, Kageyama A, Murakami T,
Shioda S, Adachi M: Lipoprotein lipase mRNA in white adipose
tissue but not in skeletal muscle is increased by pioglitazone
through PPAR-gamma.  Biochem Biophys Res Commun 2003,
305:22-27.
11. Aguilera CM, Gil-Campos M, Canete R, Gil A: Alterations in
plasma and tissue lipids associated with obesity and the met-
abolic syndrome.  Clin Sci 2008, 114:183-193.
12. Goodpaster BH, Theriault R, Watkins SC, Kelley DE: Intramuscu-
lar Lipid Content Is Increased in Obesity and Decreased by
Weight Loss.  Metabolism 2000, 49(4):467-472.
13. Athenstaedt K, Daum G: The life cycle of neutral lipids: synthe-
sis, storage and degradation.  Cellular and Molecular Life Sciences
2006, 63:1355-1369.
14. Morton MM, Holmes MC, Fievet C, Staels B, Tailleux A, Mullins JJ,
Seckl JR: Improved Lipid and Lipoprotein Profile, Hepatic
Insulin Sensitivity and Glucose Tolerance in 11beta-
Hydroxysteroid Dehydrogenase Type 1 Null Mice.  J Biol Chem
2001, 276(44):41293-41300.
15. Livingstone DEW, Walker BR: Is 11beta-Hydroxysteroid Dehy-
drogenase Type 1 a Therapeutic Target? Effects of
Carbenoxolone in Lean and Obese Zucker Rats.  J Pharmacol
Exp Ther 2003, 305(1):167-172.
16. Alberts P, Engblom L, Edling N, Forsgren M, Klingstrom G, Larsson C,
Ronquist-Nii Y, Ohman B, Abrahmsen L: Selective inhibition of
11beta-hydroysteroid dehydrogenase type 1 decreases
blood glucose concentrations in hyperglycaemic mice.  Diabe-
tologia 2002, 45:1528-1532.
17. Wamil M, Seckl JR: Inhibition of 11beta-hydroxysteroid dehy-
drogenase type 1 as a promising therapeutic target.  Drug Dis-
cov Today 2007, 12(13/14):504-520.
18. Pollare T, Vessby B, Lithell H: Lipoprotein lipase activity in the
skeletal muscle is related to insulin sensitivity.  Arterioscler
Thromb Vasc Biol 1991, 11:1192-1203.
19. Kern P: Potential Role of TNF-alpha and Lipoprotein Lipase
as Candidate Genes for Obesity.  J Nutr 1997, 127:1917S-1922S.
20. Hanyu O, Miida T, Obayashi K, Ikarashi T, Soda S, Kaneko S, Hirayama
S, Suzuki K, Nakamura Y, Yamatani K, Aizawa Y: Lipoprotein lipase
(LPL) mass in preheparin serum reflects insulin sensitivity.
Atherosclerosis 2004, 174:385-390.
21. Enerback S, Gimble JM: Lipoprotein lipase gene expression:
physiological regulators at the transcriptional and post-tran-
scriptional level.  Biochim Biophys Acta 1993, 1169:107-125.
22. Wang Y, Porter WW, Suh N, Honda T, Gribble GW, Leesnitzer LM,
Plunket KD, Mangelsdorf DJ, Blanchard SG, Willson TM, Sporn MB:
A Synthetic Triterpenoid, 2-Cyano-3,12-dioxooleana-1,9-
dien-28-oic Acid (CDDO), Is A Ligand for the Peroxisome
Proliferator-Activated Receptor Gamma.  Mol Endocrinol 2000,
14(10):1550-1556.
23. Sato M, Tai T, Nunoura Y, Yajima Y, Kawashima S, Tanaka K: Dehy-
drotrametenolic Acid Induces Preadipocyte Differentiation
and Sensitizes Animal Models of Noninsulin-Dependent Dia-
betes Mellitus to Insulin.  Biol Pharm Bull 2002, 15(1):81-86.
24. Hermanowski-Vosatka A, Balkovec JM, Cheng K, Chen HY, Hernan-
dez M, Koo GC, Le Grand CB, Li Z, Metzger JM, Mundt SS, Noonan
H, Nunes CN, Olson SH, Pikounis B, Ren N, Robertson N, Schaeffer
JM, Shah K, Springer MS, Strack AM, Strowski M, Wu K, Wu T, Xiao
J, Zhang BB, Wright SD, Thieringer R: 11beta-HSD1 inhibition
ameliorates metabolic syndrome and prevents progression
of atherosclerosis in mice.  J Exp Med 2005, 202(4):517-527.
25. Berger J, Tanen M, Elbrecht A, Hermanowski-Vosatka A, Moller DE,
Wright SD, Thieringer R: Peroxisome Proliferator-activated
Receptor-gamma Ligands Inhibit Adipocyte 11beta-
Hydroxysteroid Dehydrogenase Type 1 Expression and
Activity.  J Biol Chem 2001, 276(16):12629-12635.
26. Muoio DM, Newgard CB: Obesity-Related  Derangements in
Metabolic Regulation.  Annu Rev Biochem 2006, 75:367-401.
27. Ishida S, Sakiya Y, Ichikawa T, Taira Z, Awazu S: Prediction of Gly-
cyrrhizin Disposition in Rat and Man by a Physiologically
Based Pharmacokinetic Model.  Chem Pharm Bull 1990,
38(1):212-218.
28. McCarty M: Modulation of adipocyte lipoprotein lipase
expression as a strategy for preventing or treating visceral
obesity.  Med Hypotheses 2001, 57(2):192-200.
29. Berthiaume M, Laplante M, Festuccia WT, Cianflone K, Turcotte LP,
Joanisse DR, Olivecrona G, Thieringer R, Deshaies Y: 11beta-HSD1
inhibition improves triglyceridaemia through reduced liver
VLDL secretion and partitions lipids towards oxidative tis-
sues.  Am J Physiol Endocrinol Metab 2007, 293:E1045-E1052.
30. Staels B, Dallongeville J, Auwerx J, Schoojans K, Leitersdorf E, Fru-
chart JC: Mechanisms of Action of Fibrates on Lipid and Lipo-
protein Metabolism.  Circulation 1998, 98:2088-2093.
31. Elliot WH, Elliot DC: Energy release from fat.  In Biochemistry and
Molecular Biology 3rd edition. Oxford: Oxford University Press;
2005:226-232. 
32. Doege H, Stahl A: Protein-Mediated Fatty Acid Uptake: Novel
Insights from In Vivo Models.  Physiology 2006, 21:259-268.
33. Gibbons GF, Islam K, Pease RJ: Mobilisation of triacylglycerol
stores.  Biochim Biophys Acta 2000, 1483:37-57.
34. Dullens SPJ, Plat J, Mensink RP: Increasing apo A-I production as
a target for CHD risk reduction.  Nutr Metab Cardiovas 2007,
17:616-628.
35. Gurr MI, Harwood JL, Frayn KN: Lipid transport.  In Lipid Biochem-
istry: An Introduction 5th edition. Oxford: Blackwell Science;
2002:170-212. 
36. Tan KCB, Shiu SWM, Chu BYM: Roles of hepatic lipase and
cholesteryl ester transfer protein in determining low density
lipoprotein subfraction distribution in Chinese patients withPublish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Lipids in Health and Disease 2009, 8:31 http://www.lipidworld.com/content/8/1/31
Page 10 of 10
(page number not for citation purposes)
non-insulin-dependent diabetes mellitus.  Atherosclerosis 1999,
145:273-278.
37. Koike T, Liang J, Wang X, Ichikawa T, Shiomi M, Liu G, Sun H, Kitajima
S, Morimoto M, Watanabe T, Yamada N, Fan J: Overexpression of
Lipoprotein Lipase in Transgenic Watanabe Heritable
Hyperlipidemic Rabbits Improves Hyperlipidemia and Obes-
ity.  J Biol Chem 2004, 279(9):7521-7529.
38. Leiji FR van der, Huijkman NCA, Boomsma C, Kuipers JRG, Bartelds
B: Genomics of the Human Carnitine Acyltransferase Genes.
Mol Genet Metab 2000, 71:139-153.
39. Kane CD, Francone OL, Stevens KA: Differential regulation of
the cynomolgus, human, and rat acyl-CoA oxidase promot-
ers by PPAR-alpha.  Gene 2006, 380:84-94.
40. Kim H, Ahn Y: Role of Peroxisome Proliferator-Activated
Receptor-gamma in the Glucose-sensing Apparatus of Liver
and Beta-cells.  Diabetes 2004, 53(1):S60-S65.
41. Shimoyama Y, Hirabayashi K, Matsumoto H, Sato T, Shibata S, Inoue
H: Effects of glycyrrhetinic acid derivatives on hepatic and
renal 11beta-hydroxysteroid dehydrogenase activities in
rats.  J Pharm Pharmacol 2003, 55:811-817.
42. Quaschning T, Ruschitzka F, Niggli B, Lunt CMB, Shaw S, Christ M,
Wehling M, Luscher TF: Influence of aldosterone vs endothelin
receptor antagonism on renovascular function in liquorice-
induced hypertension.  Nephrol Dial Transplant 2001,
16:2146-2151.
43. Friedewald WT, Levy RI, Fredrickson DS: Estimation of the con-
centration of LDL-cholesterol in plasma without use of the
preparative ultracentrifuge.  Clin Chem 1972, 18:499-502.
44. Koopman R, Schaart G, Hesselink MKC: Optimisation of Oil Red
O staining permits combination with immunofluorescence
and automated quantification of lipids.  Histochem Cell Biol 2001,
116:63-68.